Physician profile
Colleen E Murphy
NPI 1316145121
$1,548.65
in general payments reported to CMS, 2019-2025
24 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $56.11 · 2021: $127 · 2022: $96.06 · 2023: $548 · 2024: $450 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,102.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $373.23 | 2022-2024 | |
| Lilly USA, LLC | $193.24 | 2021-2024 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $156.97 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $156.35 | 2023 | Rexulti |
| Novo Nordisk INC | $144.70 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Edwards Lifesciences Corporation | $94.20 | 2023-2025 | |
| Abbott Laboratories | $71.17 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Lundbeck LLC | $38.45 | 2024-2025 | Rexulti |
| Dynavax Technologies Corporation | $35.62 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $33.29 | 2019-2023 | Farxiga |
| Ethicon US, LLC | $30.14 | 2019 | |
| Gilead Sciences, INC. | $26.84 | 2024 | |
| Glaxosmithkline, LLC. | $26.40 | 2019 | |
| Exact Sciences Corporation | $20.01 | 2025 | The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $18.84 | 2024 | Veozah |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $17.96 | 2024 | Prolia, Evenity |
| Novartis Pharmaceuticals Corporation | $17.08 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $16.56 | 2021 | |
| Dexcom, INC. | $14.51 | 2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $13.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.84 | 2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.80 | 2021 | |
| Cequr Corporation | $12.00 | 2022 | |
| Merck Sharp & Dohme LLC | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.